JTC-801

CAS No. 244218-51-7

JTC-801( —— )

Catalog No. M18298 CAS No. 244218-51-7

JTC-801 is a selective opioid receptor-like1 (ORL1) receptor antagonist with IC50 of 94 nM, weakly inhibits receptors δ, κ, and μ.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 62 In Stock
5MG 39 In Stock
10MG 63 In Stock
25MG 137 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    JTC-801
  • Note
    Research use only, not for human use.
  • Brief Description
    JTC-801 is a selective opioid receptor-like1 (ORL1) receptor antagonist with IC50 of 94 nM, weakly inhibits receptors δ, κ, and μ.
  • Description
    JTC-801 is a selective opioid receptor-like1 (ORL1) receptor antagonist with IC50 of 94 nM, weakly inhibits receptors δ, κ, and μ.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Opioid receptor-like1 (ORL1)
  • Research Area
    Neurological Disease
  • Indication
    ——

Chemical Information

  • CAS Number
    244218-51-7
  • Formula Weight
    447.96
  • Molecular Formula
    C26H25N3O2·HCl
  • Purity
    >98% (HPLC)
  • Solubility
    H2O : ≥ 0.33 mg/mL; 0.74 mM
  • SMILES
    Cl.CCC1=CC=C(OCC2=CC=CC=C2C(=O)NC2=CC3=C(C=C2)N=C(C)C=C3N)C=C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Yamada H, et al. Br J Pharmacol, 2002, 135(2), 323-332.
molnova catalog
related products
  • NUC-7738

    NUC-7738 is a 5'-aryloxyphosphoamidate prodrug of 3'-dA that reduces β-catenin nuclear expression in AML cells, modulates β-catenin signaling, and can be used in cancer research.

  • PKA Regulatory Subun...

    PKA Regulatory Subunit II Substrate

  • AZD0780

    AZD0780 (EX-A6975) is an oral small molecule PCSK9 inhibitor being developed by AstraZeneca as a first-in-class treatment for patients with dyslipidemia that is uncontrolled with statins alone.